JP2023552998A5 - - Google Patents
Info
- Publication number
- JP2023552998A5 JP2023552998A5 JP2023533999A JP2023533999A JP2023552998A5 JP 2023552998 A5 JP2023552998 A5 JP 2023552998A5 JP 2023533999 A JP2023533999 A JP 2023533999A JP 2023533999 A JP2023533999 A JP 2023533999A JP 2023552998 A5 JP2023552998 A5 JP 2023552998A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- cells
- immune cells
- edited
- target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063121206P | 2020-12-03 | 2020-12-03 | |
| US63/121,206 | 2020-12-03 | ||
| US202163201159P | 2021-04-15 | 2021-04-15 | |
| US63/201,159 | 2021-04-15 | ||
| US202163236167P | 2021-08-23 | 2021-08-23 | |
| US63/236,167 | 2021-08-23 | ||
| US202163264234P | 2021-11-17 | 2021-11-17 | |
| US202163264223P | 2021-11-17 | 2021-11-17 | |
| US63/264,223 | 2021-11-17 | ||
| US63/264,234 | 2021-11-17 | ||
| PCT/US2021/072715 WO2022120370A2 (en) | 2020-12-03 | 2021-12-02 | Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023552998A JP2023552998A (ja) | 2023-12-20 |
| JP2023552998A5 true JP2023552998A5 (cg-RX-API-DMAC10.html) | 2024-12-10 |
Family
ID=81854915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023533999A Pending JP2023552998A (ja) | 2020-12-03 | 2021-12-02 | 効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240335536A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4255453A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023552998A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021392809A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3200367A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022120370A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| WO2020044239A1 (en) | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| MX2022015586A (es) * | 2020-06-12 | 2023-03-15 | Nkarta Inc | Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70. |
| CN120152722A (zh) * | 2022-06-24 | 2025-06-13 | 奥尔吉尼西丝公司 | 具有修饰的铰链和跨膜结构域的嵌合抗原受体及其用途 |
| CN117384853B (zh) * | 2022-07-11 | 2025-12-19 | 士泽生物医药(苏州)有限公司 | 一种表达pvr的通用型细胞及其制备方法 |
| CN117384852B (zh) * | 2022-07-11 | 2026-01-16 | 士泽生物医药(苏州)有限公司 | 一种表达lgals9的通用型细胞及其制备方法 |
| JP2025525864A (ja) * | 2022-08-03 | 2025-08-07 | ンカルタ・インコーポレイテッド | ナチュラルキラー細胞の機能を増強するための標的遺伝子の遺伝子編集 |
| CN120092090A (zh) * | 2022-11-07 | 2025-06-03 | 上海先博生物科技有限公司 | 工程化嵌合抗原受体免疫细胞及其应用 |
| JP2025538424A (ja) * | 2022-11-16 | 2025-11-28 | ンカルタ・インコーポレイテッド | 併用療法の投与レジメン |
| CN115948341B (zh) * | 2022-11-28 | 2025-05-16 | 上海恩凯细胞技术有限公司 | 敲低nkg2a基因的car-免疫细胞及其用途 |
| WO2024211554A1 (en) * | 2023-04-07 | 2024-10-10 | Nkarta, Inc. | Methods for treatment of autoimmune diseases |
| EP4788796A1 (en) * | 2023-10-05 | 2026-08-12 | ONK Therapeutics Limited | Optimised il-15 constructs |
| WO2025146467A1 (en) | 2024-01-04 | 2025-07-10 | Onk Therapeutics Limited | Targeted il-15 construct delivery |
| WO2026041793A1 (en) * | 2024-08-23 | 2026-02-26 | BioNTech SE | Chimeric proteins comprising non-human protein domains for enhancing antigenicity |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2752933C2 (ru) * | 2014-03-11 | 2021-08-11 | Селлектис | Способ создания т-клеток, пригодных для аллогенной трансплантации |
| WO2016142532A1 (en) * | 2015-03-11 | 2016-09-15 | Cellectis | Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients |
| US10648020B2 (en) * | 2015-06-18 | 2020-05-12 | The Broad Institute, Inc. | CRISPR enzymes and systems |
| JP7033453B2 (ja) * | 2015-06-30 | 2022-03-10 | セレクティス | 特異的エンドヌクレアーゼを使用した遺伝子不活化によってnk細胞の機能性を改善する方法 |
| MX2018010484A (es) * | 2016-03-04 | 2019-01-10 | Editas Medicine Inc | Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer. |
| WO2018126074A1 (en) * | 2016-12-30 | 2018-07-05 | Celularity, Inc. | Genetically modified natural killer cells |
| CN110168078B (zh) * | 2017-01-06 | 2024-05-14 | 免疫生物公司 | 具有降低的cd96/tigit表达的遗传修饰的nk-92细胞 |
| JP2020517259A (ja) * | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| JP2021502077A (ja) * | 2017-11-06 | 2021-01-28 | エディタス・メディシン,インコーポレイテッド | 免疫療法のためのt細胞におけるcblbのcrispr−cas9編集のための方法、組成物および構成要素 |
| WO2019178422A1 (en) * | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| SG11202010763VA (en) * | 2018-05-03 | 2020-11-27 | Univ Texas | Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade |
| AU2019386140B2 (en) * | 2018-11-28 | 2026-05-28 | Board Of Regents, The University Of Texas System | Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment |
| KR20210116526A (ko) * | 2019-01-16 | 2021-09-27 | 빔 테라퓨틱스, 인크. | 증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포 |
| BR112021016046A2 (pt) * | 2019-02-15 | 2021-11-09 | Editas Medicine Inc | Células assassinas naturais modificadas (nk) para imunoterapia |
| CN114174325A (zh) * | 2019-06-04 | 2022-03-11 | 恩卡尔塔公司 | 用于免疫疗法的工程化自然杀伤细胞和工程化t细胞的组合 |
| JP2023503652A (ja) * | 2019-11-27 | 2023-01-31 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 腫瘍微小環境における免疫抑制に打ち勝つための操作されたt細胞及び腫瘍浸潤リンパ球 |
| MX2022015586A (es) * | 2020-06-12 | 2023-03-15 | Nkarta Inc | Linfocitos citolíticos naturales modificados genéticamente para inmunoterapia de cáncer dirigida a cd70. |
| US20260000761A1 (en) * | 2022-01-19 | 2026-01-01 | Nkarta, Inc. | Engineered immune cells with enhanced potency and uses of same in immunotherapy |
-
2021
- 2021-12-02 EP EP21901656.5A patent/EP4255453A4/en active Pending
- 2021-12-02 AU AU2021392809A patent/AU2021392809A1/en active Pending
- 2021-12-02 US US18/255,222 patent/US20240335536A1/en active Pending
- 2021-12-02 WO PCT/US2021/072715 patent/WO2022120370A2/en not_active Ceased
- 2021-12-02 JP JP2023533999A patent/JP2023552998A/ja active Pending
- 2021-12-02 CA CA3200367A patent/CA3200367A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11001621B1 (en) | Trifunctional T cell-antigen coupler and methods and uses thereof | |
| US20240075143A1 (en) | Cd7-targeted engineered immune cell, chimeric antigen receptor, cd7 blocking molecule and use thereof | |
| JP6285553B2 (ja) | 抗cd30キメラ抗原受容体およびその使用 | |
| US10561686B2 (en) | Modified cell expansion and uses thereof | |
| US11566223B2 (en) | Chimeric antigen receptor cell preparation and uses thereof | |
| US11235004B2 (en) | Lymphocyte cell lines and uses thereof | |
| US20230210905A1 (en) | T cell-antigen coupler with various construct optimizations | |
| EP3980450A1 (en) | Combinations of engineered natural killer cells and engineered t cells for immunotherapy | |
| US11198737B2 (en) | T cell-antigen coupler with Y177 mutation and methods of uses thereof | |
| WO2017059796A1 (en) | Activation and expansion of t cells | |
| KR20230066007A (ko) | 신규한 보조자극 도메인을 포함하는 키메라 항원 수용체 및 이의 용도 | |
| JP2025513626A (ja) | Ciita遺伝子がノックアウトされた操作された免疫細胞及びその用途 | |
| CN117187185A (zh) | 一种工程化免疫细胞及其用途 | |
| CN115873801A (zh) | 工程化免疫细胞及其用途 | |
| WO2023035947A1 (zh) | 工程化免疫细胞及其用途 | |
| WO2023083003A1 (zh) | 工程化免疫细胞及其用途 | |
| WO2023071811A1 (zh) | 工程化免疫细胞及其用途 | |
| CN111607596A (zh) | 修饰的pd-1及其在细胞治疗中的用途 | |
| HK1234091A1 (en) | Trifunctional t cell-antigen coupler and methods and uses thereof |